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ABSTRACT
ObjeCtive
To compare the predictive accuracy and clinical utility 
of five risk scoring systems in the assessment of 
patients with upper gastrointestinal bleeding.
Design
International multicentre prospective study.
setting
Six large hospitals in Europe, North America, Asia, and 
Oceania.
PartiCiPants
3012 consecutive patients presenting over 12 months 
with upper gastrointestinal bleeding.
Main OutCOMe Measures
Comparison of pre-endoscopy scores (admission 
Rockall, AIMS65, and Glasgow Blatchford) and 
post-endoscopy scores (full Rockall and PNED) for their 
ability to predict predefined clinical endpoints: a 
composite endpoint (transfusion, endoscopic 
treatment, interventional radiology, surgery, or 30 day 
mortality), endoscopic treatment, 30 day mortality, 
rebleeding, and length of hospital stay. Optimum 
score thresholds to identify low risk and high risk 
patients were determined.
results
The Glasgow Blatchford score was best (area under the 
receiver operating characteristic curve (AUROC) 0.86) 
at predicting intervention or death compared with the 
full Rockall score (0.70), PNED score (0.69), admission 
Rockall score (0.66, and AIMS65 score (0.68) (all 
P<0.001). A Glasgow Blatchford score of ≤1 was the 
optimum threshold to predict survival without 
intervention (sensitivity 98.6%, specificity 34.6%). The 
Glasgow Blatchford score was better at predicting 
endoscopic treatment (AUROC 0.75) than the AIMS65 
(0.62) and admission Rockall scores (0.61) (both 
P<0.001). A Glasgow Blatchford score of ≥7 was the 
optimum threshold to predict endoscopic treatment 
(sensitivity 80%, specificity 57%). The PNED (AUROC 
0.77) and AIMS65 scores (0.77) were best at predicting 
mortality, with both superior to admission Rockall 
score (0.72) and Glasgow Blatchford score (0.64; 
P<0.001). Score thresholds of ≥4 for PNED, ≥2 for 
AIMS65, ≥4 for admission Rockall, and ≥5 for full 
Rockall were optimal at predicting death, with 
sensitivities of 65.8-78.6% and specificities of 
65.0-65.3%. No score was helpful at predicting 
rebleeding or length of stay.
COnClusiOns
The Glasgow Blatchford score has high accuracy at 
predicting need for hospital based intervention or 
death. Scores of ≤1 appear the optimum threshold for 
directing patients to outpatient management. AUROCs 
of scores for the other endpoints are less than 0.80, 
therefore their clinical utility for these outcomes 
seems to be limited.
trial registratiOn
Current Controlled Trials ISRCTN16235737.
Introduction
Upper gastrointestinal bleeding is a common cause of 
admission to hospital worldwide, with a UK incidence 
of 103-172 per 100 000 adults each year and mortality of 
8-14%.1-3  Many risk assessment scores have been devel-
oped to predict clinically relevant outcomes, including 
mortality, need for hospital based intervention, 
rebleeding, and length of hospital stay.4-9  Several of 
these, including the Rockall score and recently 
described progetto nazionale emorragia digestive 
(PNED) score require endoscopy before calculation.4 5 
The Rockall score has been widely reported and it has 
been suggested that the PNED score is superior to it, 
although it has not been externally validated.5  Other 
endoscopy based scores have been described but are 
not appropriate for unselected patients with upper gas-
trointestinal bleeding, have not been externally vali-
dated, or have been shown to be inferior to the Rockall 
score or PNED score.10  However, requiring endoscopy 
to calculate a score might delay risk assessment in 
WhAT IS AlReAdy knoWn on ThIS TopIC
Several pre-endoscopy and post-endoscopy risk scores have been reported to predict 
a variety of endpoints in patients presenting with upper gastrointestinal bleeding
Using low and high scores to direct patient care to outpatient management or 
urgent endoscopy and higher level care has been suggested
The accuracy and generalisability of these scores and the optimum thresholds to 
predict low risk and high risk patients to help direct care remain unclear
WhAT ThIS STudy AddS
This international study suggests that the Glasgow Blatchford score is accurate in 
predicting need for intervention, or death at all centres, with a score ≤1 the optimal 
threshold for directing low risk patients to outpatient management
All scores have low predictive accuracy for other specific outcomes, including 
endoscopic treatment and mortality, therefore their clinical utility to direct 
management of high risk patients seems limited
Widespread use of the Glasgow Blatchford score in the emergency departments of 
many countries might allow up to 19% of patients with upper gastrointestinal 
bleeding to be safely managed as outpatients
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some healthcare settings, as there can be considerable 
delays in performing endoscopy out of hours or on 
weekends.11
Recently, much interest has been shown in pre-endo-
scopic risk scores for upper gastrointestinal bleeding, 
which can be calculated shortly after presentation to 
hospital. The most widely studied scores are the abbre-
viated “admission” Rockall score, Glasgow Blatchford 
score, and recently described AIMS65 (albumin level 
<30 g/L (A), international normalised ratio >1.5 (I), 
altered mental status (M), systolic blood pressure ≤90 
mm Hg (S), and age >65 years (65)) score.7 8  These scor-
ing systems use clinical, haemodynamic, and (for 
Glasgow Blatchford and AIMS65 scores) readily avail-
able laboratory variables. Some studies have suggested 
that these scores could be used to identify patients at 
very low risk who could be managed as outpatients.12-14 
Studies have also suggested that these scores could 
identify patients at higher risk who might require 
urgent endoscopy or management in high dependency 
or intensive care units.15 16
Several studies have compared scores in their ability to 
predict various outcomes.12 16-19  Although the Glasgow 
Blatchford score seems useful in identifying very low risk 
patients in the UK many studies have been small and sin-
gle centre and no international study has compared all 
the commonly used scores. Recent guidelines have sug-
gested use of risk scores for patients with upper gastroin-
testinal bleeding, but uncertainty remains about their 
exact role in clinical practice.20-23 In this prospective 
international study we compared five endoscopic and 
pre-endoscopic risk assessment scores for their ability to 
predict clinically relevant endpoints. In addition we 
assessed the clinical utility of these scores, by determin-
ing optimal thresholds for identifying patients at very 
low risk who could be managed as outpatients, and 
higher risk patients who might require specific manage-
ment strategies aimed at improving outcome.
Methods
The study was undertaken in Yale-New Haven Hospital 
(USA), Glasgow Royal Infirmary (Scotland), Royal Corn-
wall Hospital Truro (England), Odense University Hos-
pital (Denmark), Singapore General Hospital 
(Singapore), and Dunedin Hospital (New Zealand).
The predetermined clinical endpoints were the com-
posite endpoint of need for hospital based intervention 
(red blood cell transfusion, endoscopic treatment, 
interventional radiology, or surgery) or death, endo-
scopic treatment, 30 day mortality, rebleeding within 
seven days, and length of hospital stay.
Patient management
Patients were included if they presented to the hospital 
with evidence of upper gastrointestinal bleeding 
defined by haematemesis, coffee-ground vomiting, or 
melaena. We excluded patients who developed upper 
gastrointestinal bleeding while an inpatient for another 
reason.
All patients presenting to each hospital with upper 
gastrointestinal bleeding were initially assessed in the 
emergency department or acute assessment unit. Two 
centres (Glasgow and Odense) had a policy of non-ad-
mission for those with Glasgow Blatchford scores of 1 
or less, and one centre (Truro) for those with Glasgow 
Blatchford scores of 2 or less and aged less than 70 
years, unless required for other reasons. Outpatient 
endoscopy was arranged in all three centres. Proton 
pump inhibitors (PPIs) were not routinely given to all 
admitted patients before endoscopy. The practice in all 
centres was to perform endoscopy within 24 hours in 
all admitted patients where possible. After endoscopy, 
the policy in all centres was to administer high dose 
PPIs by intravenous bolus followed by infusion to 
patients with high risk ulcer stigmata who required 
endoscopic treatment, and to other selected patients 
depending on clinical judgment.20-23  For patients with 
suspected variceal bleeding, the policy in all centres 
was to give intravenous vasopressors and antibiotics 
before endoscopy.21 24
The endoscopic practice in all centres for patients 
with high risk stigmata of non-variceal bleeding was by 
injection of dilute adrenaline (epinephrine) into and 
around the bleeding point, thermal contact or clips, or 
both, but not adrenaline alone.20-23  Band ligation or 
injection of tissue glue with or without transjugular 
intrahepatic portosystemic stent shunt was performed 
in cases of oesophageal or gastric variceal bleeding, 
respectively.21 24  In line with recent evidence and guide-
lines, the policy was to administer red blood cells at a 
haemoglobin threshold of 70-80 g/L (7-8 g/dL), or as 
guided by the clinician in patients with severe haemor-
rhage.24 25
Data collection
At each centre, data on consecutive, unselected patients 
presenting to the hospital with upper gastrointestinal 
bleeding were collected over a 12 month period between 
March 2014 and March 2015. Data on patients managed 
as outpatients in Glasgow, Truro, and Odense were also 
included. A dedicated research nurse, doctor, or medi-
cal student collected data at each site. The data col-
lected included patient characteristics and 
haemodynamic and laboratory variables at presenta-
tion necessary to calculate the full Rockall, admission 
Rockall, Glasgow Blatchford, AIMS65, and PNED scores 
(see supplementary table 1). Endoscopic findings were 
recorded.
Blood transfusion, endoscopic treatment, and inter-
ventional radiology or surgery were recorded, as was 
rebleeding within seven days, as previously defined 
(see supplementary table 2),26 30 day mortality, and 
length of hospital stay. Supplementary table 3 shows 
the collected data.
statistical analysis
We compared each scores’ ability to predict the prede-
termined outcomes, using calculation of area under the 
receiver operating characteristic curves (AUROCs) and 
95% confidence intervals. All comparisons were based 
on patients in whom all the compared scores could be 
calculated. The AUROCs were considered dependent 
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and were compared based on the method by Delong 
et al.27  The optimal score thresholds to predict patients 
at very low risk who are potentially suitable for outpa-
tient management were identified based on a sensitivity 
of 95% or more. For the other outcomes, we considered 
thresholds associated with maximum Youden index28 to 
be optimal. In addition, the performance of the scores 
was assessed by calculation of sensitivity, specificity, 
positive predictive value, negative predictive value, and 
proportion of patients classified as low risk or high risk. 
We calculated rates of transfusion, endoscopic treat-
ment, and mortality for those classified as low risk. Pro-
portions were compared using Pearsons χ2 test and 
Fischer’s exact test. Medians were compared using the 
Mann-Whitney U test and the Kruskal-Wallis equality of 
populations rank test.
We aimed for an adequate sample size to compare all 
the predetermined outcomes. Existing data indicated 
that the highest power was needed for comparative 
analyses on mortality. Therefore assuming AUROCs of 
0.86 for mortality, 0.78 for AIMS65 score8 20  and full 
Rockall score,10 21  with an α of 5%, power of 90%, rank 
correlation of 0.5, and mortality of 5%,13 we determined 
that we required a sample size of 2814 patients. We used 
a two tailed significance level of 5%. Data analysis was 
undertaken using STATA 11.0 (StataCorp, College Sta-
tion, TX).
Only the local principal investigator and dedicated 
nurse, junior doctor, or medical student had access to 
the identifiable data from their centre, with the anony-
mised data sent to SBL and AJS for central analysis. Our 
report follows STROBE guidelines.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for recruitment, design, or implemen-
tation of the study. No patients were asked to advise on 
interpretation or writing up of results. There are no 
plans to disseminate the results of the research to study 
participants or the relevant patient community.
Results
Patient characteristics and baseline scores
A total of 3012 patients were included in the study, with 
2868 (95%) followed up for 30 days. The median age of 
patients was 65 years, and 58% were men. Table 1 shows 
the patients’ characteristics, endoscopic findings, inter-
ventions, and outcomes. A total of 1348 (45%) patients 
needed hospital based intervention or died within 30 
days. Endoscopic treatment was performed in 574 
(19%), 37 (1.2%) required interventional radiology or 
surgery, and 144 (5%) rebled within seven days. The 
median length of stay was 3 days (95% confidence inter-
val 0 to 16 days), and 30 day mortality was 7%. Overall, 
the mean Glasgow Blatchford score was 6.6 (95% confi-
dence interval 0 to 14), mean AIMS65 score was 1 (0 to 
3), mean admission Rockall score was 2.7 (0 to 5), mean 
full Rockall score was 3.9 (1 to 7), and mean PNED score 
was 3.0 (0 to 8). Supplementary table 4 show these data 
by centre.
Comparison of scores’ ability to predict outcomes
Intervention or mortality
The Glasgow Blatchford score had the highest discrimi-
native ability (AUROC 0.86) at predicting need for inter-
vention or death compared with the PNED score (0.69; 
P<0.001), full Rockall score (0.70; P<0.001), admission 
Rockall score (0.66 P<0.001), and AIMS65 score (0.68; 
P<0.001) (table 2  and fig 1). The Glasgow Blatchford 
score performed consistently well in all centres, with 
AUROCs ranging between 0.85 and 0.91 (see supple-
mentary table 5). However, performance of AIMS65 and 
the full Rockall scoring systems varied by centre, with 
AUROCs ranging from 0.54-0.75 and 0.57-0.79, respec-
tively. AUROCs among centres were 0.59-0.72 for 
 admission Rockall score and 0.70-0.76 for PNED score 
(see supplementary table 5).
Tables 3  shows the ability of the three pre-endo-
scopic scores to predict patients at very low risk who did 
not require intervention and survived at optimal cut-
offs. A Glasgow Blatchford score of 1 or less had a sensi-
tivity of 98.6%, specificity of 34.6%, positive predictive 
value of 96.6%, and negative predictive value of 56.0% 
for this combined endpoint. Intervention or death was 
recorded in 3.4% of the 564 patients with Glasgow 
Blatchford scores of 1 or less, compared with 14% of the 
table 1 | Characteristics, treatment, and outcome of 
patients (n=3012). values are numbers (percentages) 
unless stated otherwise
Characteristics Data
Median (95% CI) age (years) 65 (24 to 90)
Men 1750 (58)
Comorbidity:
 Ischaemic heart disease 580 (19)
 Liver disease 453 (15)
 Renal failure 266 (9)
 Any malignancy 430 (14)
Median (95% CI) systolic blood pressure (mm Hg) 125 (90 to 170)
Median (95% CI) pulse 89 (61 to 126)
Median (95% CI) haemoglobin level (g/L) 112 (58 to 162)
Findings at endoscopy:
 Nothing abnormal 297 (14)
 Erosive disease* 583 (28)
 Gastric/duodenal ulcer 572 (28)
 Variceal bleeding 143 (7)
 Upper gastrointestinal cancer 70 (3)
No endoscopy 937 (31)
Median (95% CI) time to endoscopy (hours) 19 (3 to 72)
Treatment:
 Median (95% CI) No of transfusions 1.3 (0 to 6)
 Endoscopic treatment 574 (19)
 Surgery/interventional radiology 37 (1.2)
Outcome:
 No need for intervention, or death 1636 (55)
 Rebleeding 144 (5)
 Mortality 208 (7)
Mean (95% CI) score:
 Glasgow Blatchford 6.6 (0 to 14)
 AIMS65 1.0 (0 to 3)
 Admission Rockall 2.7 (0 to 5)
 Full Rockall 3.9 (1 to 7)
 PNED 3.0 (0 to 8)
*Oesophagitis, gastritis, or duodenitis.
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436 patients with admission Rockall scores of 0, and 
25% of the 865 patients with AIMS65 scores of 0 (see 
table 3). The most common intervention in those with 
Glasgow Blatchford scores of 1 or less was blood trans-
fusion, with endoscopic treatment performed in 1.4% 
and overall mortality 0.4%. The proportion of low risk 
patients defined by Glasgow Blatchford scores of 1 or 
less varied by site, ranging from 9% in Dunedin to 31% 
in Glasgow.
Endoscopic treatment
The Glasgow Blatchford score (AUROC 0.75) performed 
better in predicting need for endoscopic treatment than 
the other pre-endoscopic scores: AIMS65 (0.62) and 
admission Rockall (0.61; P<0.001 for both; fig 2 ). The 
Glasgow Blatchford scoring system performed equally 
well in predicting this endpoint in all centres (see sup-
plementary table 5). A threshold Glasgow Blatchford 
score of 7 or more was best at predicting endoscopic 
treatment, with a sensitivity of 80.4%, specificity of 
57.4%, positive predictive value of 31.3%, and negative 
predictive value of 92.4% (table 4).
Mortality
The AIMS65 score (AUROC 0.77) and PNED score (0.77) 
had similar discriminative abilities for predicting 30 
day mortality (table 2  and fig 3 ). The PNED score was 
better at predicting mortality than the admission 
 Rockall score (0.72; P=0.05), full Rockall score (0.72; 
P=0.05), and Glasgow Blatchford score (0.64; P<0.001). 
AIMS65 was better at predicting mortality than the 
Glasgow Blatchford score (P<0.001) and admission 
Rockall score (P=0.05). Furthermore, the AIMS65 score 
had a near statistically significantly higher AUROC com-
pared with the full Rockall score (P=0.06). The best 
score thresholds at predicting 30 day mortality were 4 
or more for PNED, 2 or more for AIMS65, 4 or more for 
admission Rockall, 5 or more for full Rockall, and 5 or 
more for Glasgow Blatchford. Table 5 shows the predic-
tive ability of all five scores to identify high risk patients.
Rebleeding and length of stay
PNED, which includes rebleeding in the score, was best 
(AUROC 0.85) at predicting rebleeding compared with 
the Glasgow Blatchford score (0.66; P<0.001), full Rock-
all score (0.64; P<0.001), admission Rockall score (0.62; 
P<0.001), and AIMS65 (0.60; P<0.001). The Glasgow 
Blatchford score was better at predicting rebleeding 
compared with the AIMS65 score (P=0.04). All risk 
scores had poor discriminative abilities for predicting 
length of stay for more than three days. The AUROCs 
were 0.68 for PNED score, 0.65 for full Rockall score, 
0.64 for admission Rockall score, 0.63 for Glasgow 
Blatchford score, and 0.61 for AIMS65 score.
Missing values
Values were missing for the Glasgow Blatchford score 
(n=80), AIMS65 score (n=511), admission Rockall score 
(n=43), full Rockall score (n=1000), PNED score (n=178), 
comorbidity (n=1), systolic blood pressure (n=41), pulse 
(n=38), haemoglobin concentration (n=28), findings at 
endoscopy (n=2), true low risk status (n=28), total units 
of blood transfused (n=23), performance of endoscopic 
treatment (n=20), performance of surgery or interven-
tional radiology (n=5), rebleeding (n=51), and mortality 
(n=1). Comparisons of AUROCs were undertaken using 
table 2 | Discriminative ability of evaluated scoring 
systems
Outcome by scoring system aurOC (95% Ci)
Intervention or death:
 Glasgow Blatchford 0.89 (0.87 to 0.90)
 AIMS65 0.70 (0.68 to 0.72)
 Admission Rockall 0.69 (0.67 to 0.71)
 Full Rockall 0.69 (0.67 to 0.71)
 PNED 0.71 (0.70 to 0.73)
Need for endoscopic treatment:
 Glasgow Blatchford 0.75 (0.73 to 0.77)
 AIMS65 0.63 (0.60 to 0.65)
 Admission Rockall 0.61 (0.59 to 0.64)
Rebleeding:
 Glasgow Blatchford 0.70 (0.66 to 0.74)
 AIMS65 0.62 (0.57 to 0.66)
 Admission Rockall 0.62 (0.57 to 0.66)
 Full Rockall 0.63 (0.58 to 0.68)
 PNED 0.85 (0.83 to 0.88)
Mortality:
 Glasgow Blatchford 0.69 (0.66 to 0.72)
 AIMS65 0.78 (0.75 to 0.81)
 Admission Rockall 0.76 (0.73 to 0.79)
 Full Rockall 0.72 (0.68 to 0.77)
 PNED 0.79 (0.76 to 0.82)
AUROC=Area under receiver operating characteristic curve.
Values represent all patients with available data.
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Fig 1 | Comparisons of scores in prediction of need for any 
intervention (transfusion, endoscopic treatment, 
interventional radiology or surgery) or 30 day mortality 
(n=1704). all figures compare patients with complete data 
for all compared scores. aurOC=area under the receiver 
operating characteristic curve
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complete case analysis. Data for all pre-endoscopic 
scores (admission Rockall, AIMS65, Glasgow Blatch-
ford) were available in 2495 (83%) patients, and data for 
both post-endoscopy scores (full Rockall, PNED) in 1922 
(64%). Data for the endoscopic treatment endpoint and 
the composite endpoint were available in 2478 (82%) 
and 1707 (57%) patients, respectively.
Patients with missing values for full Rockall or 
AIMS65 had lower Glasgow Blatchford scores (mean: 
4.8 (95% confidence interval 0.0 to 13.0) v 7.8 (1 to 14); 
P<0.001), PNED scores (mean: 2.6 (0.0 to 7.0) v 3.2 (0.0 to 
8.0); P<0.001), and admission Rockall scores (mean: 2.5 
(0 to 5) v 2.9 (0 to 5); P<0.001) compared with patients 
without missing data for these two scores. Patients with 
missing values for full Rockall score or AIMS65 less 
often underwent hospital based intervention or died 
(27% v 58%; P<0.001) but had similar 30 day mortality 
(7.5% v 6.5%; P=0.32) compared with patients without 
missing values for these scores. Analysis from the cen-
tre with the lowest missing data on AIMS65 and full 
Rockall scores (Odense, at 1.9% and 8.3% respectively) 
showed that the Glasgow Blatchford score had a higher 
discriminative ability to predict need for intervention, 
or death, and need for endoscopic treatment, compared 
with all other risk scores (P<0.001; see supplementary 
table 5).
discussion
This international multicentre study shows that the 
Glasgow Blatchford score is an accurate risk score at all 
sites for predicting need for clinical intervention, or 
death, after upper gastrointestinal bleeding. Although 
scores for AIMS65 and PNED are the best for predicting 
mortality and the Glasgow Blatchford score is best for 
predicting endoscopic treatment, accuracy and clinical 
utility is relatively low for these endpoints.
strengths and limitations of this study
Strengths of our study include its international multi-
centre design and large number of consecutive patients 
studied. By assessing the five pre-endoscopy and 
post-endoscopy scores that appeared most promising 
for clinical use, we could investigate the optimum way 
to risk assess patients with upper gastrointestinal 
bleeding, both early after presentation and after endo-
scopic diagnosis and treatment. We believe our choice 
of several clinically relevant endpoints in addition to a 
composite endpoint to compare the scores provides cli-
nicians with useful information. Clinicians may be keen 
to identify those at high risk for need of endoscopic 
table 3 | Outcomes at optimal thresholds of glasgow blatchford score, aiMs65, and admission rockall score in prediction of need for intervention, or 
death. values are numbers (percentages) unless stated otherwise
scoring system Cut-off low risk patients* sensitivity (%) specificity (%) PPv (%) nPv (%)
received 
transfusion
endoscopic 
treatment
surgery or 
interventional 
radiology† Mortality‡
Glasgow Blatchford ≤1 564 (19.2) 98.6 34.6 96.6 56.0 10 (1.8) 8 (1.4) 2 (0.4) 2 (0.4)
AIMS65 0 865 (34.6) 81.5 49.9 74.7 59.9 165 (19) 107 (12) 9 (1.0) 6 (0.7)
Admission Rockall 0 436 (14.7) 95.6 23.4 86.5 50.9 41 (9.4) 29 (6.7) 0 (0) 1 (0.2)
PPV=positive predictive value; NPV=negative predictive value.
Several patients fulfilled more than one endpoint.
*Classified as low risk according to risk scoring system.
†Number (%) of patients needing surgery, or arterial embolisation among patients classified as low risk.
‡Number (%) of patients dying within 30 days from presentation among patients classified as low risk.
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Fig 2 | Comparisons of pre-endoscopic scores in prediction 
of need for endoscopic treatment (n=2478). aurOC=area 
under the receiver operating characteristic curve
table 4 | need for endoscopic treatment at optimal score thresholds of each of the pre-endoscopic scores: glasgow 
blatchford score, aiMs65, and admission rockall score
scoring system Cut-off
no (%) of patients 
classified as high risk sensitivity (%) specificity (%) PPv (%) nPv (%)
Glasgow Blatchford ≥7 1456 (50) 80.4 57.4 31.3 92.4
AIMS65 ≥1 1619 (65) 79.7 38.7 25.9 87.6
Admission Rockall ≥3 1686 (57) 69.8 45.9 23.5 86.5
PPV=positive predictive value; NPV=negative predictive value.
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treatment, to direct such patients to urgent endoscopy. 
Similarly, those at high risk of death could be moved to 
areas of higher level care. While a potential weakness of 
composite endpoints is that they may be driven largely 
by one or two components and thus might not provide 
useful information if the components are not clinically 
appropriate to combine, we believe our composite end-
point is clinically useful because it includes the out-
comes that generally would necessitate admission to 
hospital. Furthermore, this composite endpoint has 
been used in several previous studies in this area.12 13 29 
Using our composite endpoint, if patients can be iden-
tified as unlikely to need transfusion or haemostatic 
intervention, or die, then most doctors would be com-
fortable discharging them from the emergency depart-
ment for outpatient management.
A weakness of our study was that we excluded 
patients who were already inpatients when they devel-
oped upper gastrointestinal bleeding. These patients 
are already known to be at high risk of poor outcome. In 
addition, 31% of patients did not undergo endoscopy. In 
three centres, there was a guideline to not admit 
patients with Glasgow Blatchford scores of either 1 or 
less or 2 or less and aged less than 70 years, and many 
did not attend for outpatient endoscopy. In addition, 
some clinicians decided endoscopy was not required 
after an apparent trivial bleed, or was deemed inappro-
priate for some ill patients with multiple comorbidities. 
Interestingly, the UK national audit on upper gastroin-
testinal bleeding reported that 26% of patients notified 
to gastroenterologists did not have inpatient endos-
copy.11 We do not believe this had a major effect on our 
study findings, as 95% of patients were followed up for 
30 days after presentation. Importantly, the usefulness 
of risk scores that require endoscopy is limited because 
endoscopy (if undertaken) is often delayed for up to 24 
hours or more, whereas clinicians generally want risk 
stratification early after presentation.
A fairly large number of patients had missing values 
for full Rockall score (largely as a result of not undergo-
ing endoscopy) or AIMS65 score (largely due to lack of 
measurement of albumin). Although 30 day mortality 
was similar in patients with and without missing values 
for both scoring systems, those with missing values had 
lower values of the other scores and less often under-
went intervention, which could lead to an underestima-
tion of the ability of the AIMS65 score to identify low 
risk patients. However, in the centre with the lowest 
missing values for AIMS65 score (Odense at 1.9%), sub-
group analysis confirmed our main finding that the 
Glasgow Blatchford score had a higher discriminative 
ability to predict need for intervention or death com-
pared with other risk scores, including AIMS65.
All data on patients managed as outpatients were 
included. In these outpatients, apart from performance 
of endoscopy they were otherwise assessed, investi-
gated, and managed in the same way as all others and 
were followed up at 30 days using patient records. None 
of those managed as outpatients died and none 
required transfusion, surgery, or interventional radiol-
ogy; endoscopic treatment was undertaken in one (a 28 
year old with a minor Mallory-Weiss tear.). Therefore we 
do not believe that these policies had a major impact on 
our conclusions.
The power calculation for mortality was based on 
AIMS65 and full Rockall scores. Using our baseline 
assumptions, the number of patients in our study with 
full data on AIMS65 and full Rockall scores still pro-
vided 80% power to predict mortality. For our primary 
endpoint of intervention or death, using previous 
AUROC data for AIMS65 score of 0.7 and for the Glasgow 
Blatchford score of 0.8 (worst case value) and power of 
90%, we needed only approximately 500 patients.30 
table 5 | 30 day mortality at optimal score thresholds of glasgow blatchford score, aiMs65, PneD, and full rockall score
scoring system Cut-off
no (%) of high 
risk patients* sensitivity (%) specificity (%) PPv (%) nPv (%)
AIMS65 ≥2 672 (26.9) 65.8 76.2 18.0 96.6
PNED ≥4 1065 (37.6) 77.3 65.3 14.1 97.5
Admission Rockall ≥4 1130 (38.1) 78.6 65.0 14.3 97.6
Full Rockall ≥5 815 (40.5) 74.0 61.7 11.1 97.3
Glasgow Blatchford ≥5 1812 (61.8) 88.7 40.2 9.9 97.9
PPV=positive predictive value; NPV=negative predictive value.
*Classified as high risk according to risk scoring system.
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Therefore we believe we achieved sufficient power in 
this study, which is the largest prospective study on this 
topic to date.
Comparison with other studies
A recent single centre retrospective study from Australia 
of 424 patients with upper gastrointestinal bleeding com-
pared all these scores apart from PNED.31  The researchers 
reported that the AIMS65 score was best at predicting 
mortality with a similar AUROC to ours, although lower 
than other smaller studies.16 19 29 They also found that 
AIMS65, Glasgow Blatchford, and full Rockall scores 
were similar at predicting their composite endpoint, 
which unlike ours did not include blood transfusion. 
However, we believe this is an important endpoint to 
assess, particularly for identification of low risk patients 
for possible outpatient management. A variety of low 
and high risk score thresholds have been suggested for 
clinical use by these and other small studies.
Published guidelines suggest outpatient management 
for patients with a Glasgow Blatchford score of 0.20 21 23 
Some authors, however, have suggested that this low 
risk threshold could be extended to 1 or less or to 2 or 
less.13 14 22  We identified a Glasgow Blatchford score of 1 
or less as the optimum score threshold to identify 
patients who would not require intervention or die, with 
a sensitivity of 98.6%. The accuracy of this threshold 
was consistently high across international sites, which 
comprised 19% of all patients in our study, compared 
with the 8.6% patients who had a Glasgow Blatchford 
score of 0. Of the patients with a Glasgow Blatchford 
score of 1 or less, all cause mortality was only 0.4%. This 
compares favourably with accepted low risk thresholds 
of commonly used scores for other medical conditions, 
including CURB65 for chest infection and the pulmo-
nary embolism severity index.32 33 Other studies have 
reported more accurate prediction of death, rebleeding, 
or length of stay using these scores, but our study has 
the advantages of a multicentre design and large num-
bers of participants and suggests these outcomes are not 
well predicted by the studied scores.
The median length of hospital admission for a patient 
presenting with upper gastrointestinal bleeding in the 
UK is four or five days,3 12  and a recent study showed the 
mean in-hospital cost to be £2458 ($3087; €2909) per 
patient.34  Use of an accurate score within emergency 
departments or acute assessment units, to identify very 
low risk patients with upper gastrointestinal bleeding 
not requiring admission has clear benefits. Interest-
ingly, sites varied in the proportion of very low risk 
patients defined by a Glasgow Blatchford score of 1 or 
less. The differences are probably due to different mod-
els of healthcare provision, including extent of primary 
care services. At the other end of the spectrum of sever-
ity of upper gastrointestinal bleeding, early identifica-
tion of high risk patients who might benefit from urgent 
endoscopy or higher level care could help guide man-
agement. An observational study suggested that 
patients with a Glasgow Blatchford score greater than 12 
have decreased mortality if endoscopy is undertaken 
less than 13 hours after presentation.19 Our data suggest 
that a Glasgow Blatchford score of 7 or more and 
AIMS65 score of 2 or more have the highest combination 
of sensitivity and specificity for predicting endoscopic 
treatment or 30 day mortality, respectively, but the pos-
itive predictive value for both is low. Therefore the 
 clinical utility of these scores to direct care in high risk 
patients seems limited.
Conclusions and policy implications
The Glasgow Blatchford score is accurate at predicting 
need for clinical intervention, or death in patients with 
upper gastrointestinal bleeding in all countries studied. 
A score of 1 or less is the optimum threshold for identi-
fying very low risk patients suitable for outpatient man-
agement. A Glasgow Blatchford score of 7 or more is 
best at predicting need for endoscopic treatment, and a 
PNED score of 4 or more and AIMS65 score of 2 or more 
are best at predicting mortality, although accuracy in 
predicting these endpoints is relatively low. No score 
seems accurate at predicting rebleeding or length of 
hospital stay. This information can help direct manage-
ment of very low risk patients with upper gastrointesti-
nal bleeding, but further studies using these, or new 
scores, are required to clarify their role in directing 
management of higher risk patients.
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